Protocol Ledger

NCT07106632 · Phase III · RECRUITING

Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests

Interventional Phase III clinical trial protocol NCT07106632 sponsored by UNICANCER in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-06-26 Enrollment: 3,380 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07106632
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)3,380 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07106632
Protocol FieldVerified Registry Value
NCT IdentifierNCT07106632
Consolidated Lead SponsorUNICANCER
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment3,380 participants (ESTIMATED)
Registered Start Date2026-06-26
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07106632
Hospital Research SiteLocationSite Profile
Institut Jules BordetBrussels, BelgiumOpen Hospital Dossier ->
Cliniques Universitaires Saint-LucBrussels, BelgiumOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI